These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30711279)

  • 1. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival.
    Solomon D; Deeb AL; Tarabine K; Xie Y; Mazzola E; Zhao L; Hammer MM; Jaklitsch MT; Swanson SJ; Bueno R; Wee JO
    J Thorac Cardiovasc Surg; 2024 Jul; 168(1):278-289.e4. PubMed ID: 37967764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
    Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
    Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
    J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
    Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
    Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.